Comparing two chemotherapy regimens with Camrelizumab for advanced nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of two chemotherapy regimens, nab-TPC and GP, when combined with the immunotherapy drug Camrelizumab in patients with recurrent or metastatic nasopharyngeal carcinoma. The study will compare the therapeutic effects of these combinations, focusing on patient survival and side effects. Previous studies have indicated that anti-PD-1 inhibitors like Camrelizumab can significantly improve outcomes in this patient population, making this trial particularly relevant. The trial is designed as a phase III study, indicating a robust approach to assess the treatment's effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age over 18 years.
2. ECOG score of 0-1.
3. Expected survival of at least 12 weeks.
4. Recurrent/Metastatic Nasopharyngeal Carcinoma.
5. At least 4 weeks since the previous chemotherapy.
6. At least one (according to RECIST) measurable lesion, lesions that have been previously irradiated can not be considered target lesions.
7. had adequate organ function

Where it's running

• SunYat-senU
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Xiang Yanqun
• Email: xiangyq@sysucc.org.cn
• Phone: 02087343379

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies

  This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.

  Recruiting Phase 2 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT07896096

• Nanocrystalline Megestrol Acetate to Help Appetite During Chemoradiotherapy in Nasopharyngeal Carcinoma

  This phase 3 trial tests whether taking nanocrystalline megestrol acetate can help people with nasopharyngeal carcinoma who are receiving chemoradiotherapy to keep their appetite and weight better than placebo.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT07796789

• Interferon-gamma plus camrelizumab with chemotherapy before surgery for locally advanced esophageal squamous cell carcinoma

  This trial tests whether giving interferon-gamma with camrelizumab and chemotherapy before surgery helps patients with locally advanced esophageal squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Hefei Cancer Hospital of the Chinese Academy of Sciences · Hefei, Anhui and 1 other locations · NCT07787273

• Becotatug Vedotin plus Anti-PD-1 as maintenance for recurrent/metastatic NPC

  This phase 3 trial tests whether adding becotatug vedotin to an anti-PD-1 therapy as maintenance can help people with recurrent or metastatic nasopharyngeal cancer who have stable disease after initial treatment.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07705243

• Camrelizumab with Famitinib for rare head and neck cancers

  This trial tests whether combining camrelizumab with famitinib can help adults with unresectable or metastatic soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or certain salivary gland cancers who have not tried a PD-1 inhibitor before.

  Recruiting Phase 1/2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07662681

• Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer

  This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.

  Recruiting Phase 1 West China Hospital · Chengdu, China · NCT07625423

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.